Management of prostate cancer

British Journal of Hospital Medicine

Volumn 73, Issue 2, 2012, Pages 95-99

  Eylert, M F ^a   Persad, R ^b  

^a MORRISTON HOSPITAL   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857883125     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2012.73.2.95     Document Type: Review

References (13)

1. Albertson PC (2011) When is active surveillance the appropriate treatment for prostate cancer? Acta Oncol 50(suppl 1):120-6
2. Bahl A, Persad R (2011) Metastatic castrate-resistent prostate cancer: new landscape, new challenges. Br J Med Surg Urol 4(suppl 1):S9-S13
3. Bul M, Schröder F (2011) Screening for prostate cancer - the controversy continues, but can it be resolved? Acta Oncol 50(suppl 1):4-11
4. Cancer Research UK (2011) Prostate cancer statistics - Key Facts. info. cancerresearchuk.org/cancerstats/keyfacts/prostate-cancer/ (accessed 23 October 2011)
5. Cheng L, Jones TD, Pan C, Barbarin A, Eble JN, Koch MO (2005) Anatomic distribution and pathologic characterisation of smallvolume prostate cancer (<0.5ml) in whole-mount prostatectomy specimens. Modern Pathol 18:1022-6 (Pubitemid 41224491)
6. Franks L (1954) Latent carcinoma. Ann Royal Coll Surg Eng 15(4):236-49
7. Heidenreich A, Bolla M, Joniau S et al (2011) Guidelines on prostate cancer. In: European Association of Urology guidelines. 2011 edition. Drukkereij Gelderland bv, Arnhem
8. Ilic D, O'Connor D, Green S, Wilt TJ (2011) Screening for prostate cancer: an updated Cochrane systematic review. BJU Int 107(6):882-91
9. Johansson JE, Adami HO, Andersson SO, Berstrom R, Holmberg L, Krusemo UB (1992) High 10-year survival rate in patients with early, untreated prostate cancer. JAMA 267:2191-6
10. Milecki P, Kwias Z, Martenka DJ (2007) Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis. Neoplasma 54(1):7-15
11. Nguyen CT, Jones JS (2011) Focal therapy in the management of localised prostate cancer. BJU Int 107(9):1362-8
12. NHS Cancer Screening Programmes (2011) Prostate cancer risk management programme. www.cancerscreening.nhs.uk/prostate/index.html (accessed 19 November 2011)
13. Payne HA, Aggarwal A, Woolf DK (2011) The evolution and current paradigm of chemotherapy for metastatic castrate-resistant prostate cancer. Br J Med Surg Urol 4(suppl 1):S2-S8